Showing 1681-1690 of 3223 results for "".
- Conbercept Treatment of Wet AMD Completes 36-Week Primary Endpoint Visits of Phase 3 Trialhttps://modernod.com/news/conbercept-treatment-of-wet-amd-completes-36-week-primary-endpoint-visits-of-phase-3-trial/2478698/China-based Chengdu Kanghong Pharmaceutical Group announced a key development milestone of its key product conbercept last month. Kanghong is seeking global approval of conbercept by undertaking a multicenter, multinational, d
- Last Patient, Last Visit Completed in RegeneRx Phase 3 Dry Eye Clinical Trialhttps://modernod.com/news/last-patient-last-visit-completed-in-regenerx-phase-3-dry-eye-clinical-trial/2478508/RegeneRx Biopharmaceuticals announced that the final patient in its 700 subject, ARISE-3 phase 3 clinical trial for dry eye syndrome has completed treatment and follow-up. ARISE-3 is designed to assess the safety and efficacy of 0.1% RGN-259 eye drops compared to placebo after 2 weeks of
- Survey: 80% of Consumers Would Be More Likely To Visit a Doctor if They Could See the Exact Out-of-Pocket Cost On Their Smartphonehttps://modernod.com/news/survey-80-of-consumers-would-be-more-likely-to-visit-a-doctor-if-they-could-see-the-exact-out-of-pocket-cost-on-their-smartphone/2476190/Metova, a provider of mobile, connected car, connected home and IoT Solutions, announced findings from a “Mobile First” survey on health care and technology, revealing the sentiment of over 1,000 consumers who currently have health care. The survey was conducted to research the growin
- Devlyn Optical Partnering with Eyenuk to Offer Diabetic Retinopathy Screeninghttps://modernod.com/news/devlyn-optical-partnering-with-eyenuk-to-offer-diabetic-retinopathy-screening/2477858/Eyenuk and Devlyn Optical, an optical retailer with over 1,000 stores in Mexico, Guatemala, El Salvador, and the US, announced that they will collaborate to pilot diabetic retinopathy (DR) screening services at Devlyn
- Alcon to Showcase Latest Innovations at AAO 2024 Annual Meetinghttps://modernod.com/news/alcon-to-showcase-latest-innovations-at-aao-2024-annual-meeting/2482489/Alcon will unveil its latest clinical data and product innovations at the American Academy of Ophthalmology (AAO) 2024 annual meeting. Attendees, including ophthalmologists, surgical staff, researchers, and industry leaders, are invited to visit Alcon at booth #4008 for hands-on demonstrations an
- Graybug Vision Completes Treatment Phase of ALTISSIMO Trial in Wet AMD with 12-Month Topline Datahttps://modernod.com/news/graybug-vision-completes-treatment-phase-of-altissimo-trial-in-wet-amd-with-12-month-topline-data/2478738/Graybug Vision announced the last patient visit in its GB-102 phase 2b ALTISSIMO core trial (the 12-month treatment phase) in wet age-related macular degeneration (AMD). ALTISSIMO 12-month topline data are expected to be announced in the second quarter of 2021, with full results to b
- Alcon Launches New Multifocal Advertising Campaign to Increase Awareness of Contact Lens Optionshttps://modernod.com/news/alcon-launches-new-multifocal-advertising-campaign-to-increase-awareness-of-contact-lens-options/2480111/Alcon has launched its “See Near and Far” direct-to-consumer campaign to increase consumer awareness of multifocal contact lens options and encourage them to visit an eye care professional (ECP). The campaign will include a television spot that will run on ABC, NBC, CBS, and ESPN, among others, t
- Oklahoma, Texas and Alaska to Begin Allowing Elective Surgerieshttps://modernod.com/news/oklahoma-texas-and-alaska-to-begin-allowing-elective-surgeries/2477618/Texas, Oklahoma, and Alaska are among the first states to begin reopening their economies, including allowing elective surgeries to resume, following the release of new guidance from the White House this week, according to a FierceHealthcare
- SightGlass Vision Reports 4-Year Clinical Trial Outcomes for Myopia Control DOT Spectacle Lenseshttps://modernod.com/news/sightglass-vision-reports-4-year-clinical-trial-outcomes-for-myopia-control-dot-spectacle-lenses/2481810/SightGlass Vision reported positive 4-year outcomes from its pivotal CYPRESS study extension, which is evaluating the myopia control performance of the company’s Diffusion Optics Technology (DOT 0.2) spectacle lenses. The lenses use thousands of light scattering el
- Aurion Biotech Announces IOTA Cell Therapy Trialhttps://modernod.com/news/aurion-biotech-announces-iota-cell-therapy-trial/2479415/Aurion Biotech announced preliminary findings from its IOTA trial, conducted in November 2020 and in May of this year, at the Clínica Quesada in San Salvador, El Salvador. In the IOTA trial, 50 patients diagnosed with corneal endothelial disease were treated with a transformational cell th